212 related articles for article (PubMed ID: 34174440)
1. Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning.
Schwarzer A; Talbot SR; Selich A; Morgan M; Schott JW; Dittrich-Breiholz O; Bastone AL; Weigel B; Ha TC; Dziadek V; Gijsbers R; Thrasher AJ; Staal FJT; Gaspar HB; Modlich U; Schambach A; Rothe M
Mol Ther; 2021 Dec; 29(12):3383-3397. PubMed ID: 34174440
[TBL] [Abstract][Full Text] [Related]
2. Development of an
Bastone AL; Dziadek V; John-Neek P; Mansel F; Fleischauer J; Agyeman-Duah E; Schaudien D; Dittrich-Breiholz O; Schwarzer A; Schambach A; Rothe M
Mol Ther Methods Clin Dev; 2023 Sep; 30():515-533. PubMed ID: 37693949
[TBL] [Abstract][Full Text] [Related]
3. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
Wu C; Dunbar CE
Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
[TBL] [Abstract][Full Text] [Related]
4. Retroviral vectors: post entry events and genomic alterations.
Nowrouzi A; Glimm H; von Kalle C; Schmidt M
Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
[TBL] [Abstract][Full Text] [Related]
5. Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice.
Montini E; Cesana D
Methods Enzymol; 2012; 507():171-85. PubMed ID: 22365774
[TBL] [Abstract][Full Text] [Related]
6. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
7. Viral Vectors: The Road to Reducing Genotoxicity.
David RM; Doherty AT
Toxicol Sci; 2017 Feb; 155(2):315-325. PubMed ID: 27803388
[TBL] [Abstract][Full Text] [Related]
8. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
[TBL] [Abstract][Full Text] [Related]
9. The long terminal repeat negative control region is a critical element for insertional oncogenesis after gene transfer into hematopoietic progenitors with Moloney murine leukemia viral vectors.
Ikawa Y; Uchiyama T; Jagadeesh GJ; Candotti F
Gene Ther; 2016 Nov; 23(11):815-818. PubMed ID: 27487944
[TBL] [Abstract][Full Text] [Related]
10. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.
Montini E; Cesana D; Schmidt M; Sanvito F; Bartholomae CC; Ranzani M; Benedicenti F; Sergi LS; Ambrosi A; Ponzoni M; Doglioni C; Di Serio C; von Kalle C; Naldini L
J Clin Invest; 2009 Apr; 119(4):964-75. PubMed ID: 19307726
[TBL] [Abstract][Full Text] [Related]
11. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
Trobridge GD
Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the in vivo safety of insulated foamy viral vectors.
Browning DL; Everson EM; Leap DJ; Hocum JD; Wang H; Stamatoyannopoulos G; Trobridge GD
Gene Ther; 2017 Mar; 24(3):187-198. PubMed ID: 28024082
[TBL] [Abstract][Full Text] [Related]
13. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.
Bauer G; Dao MA; Case SS; Meyerrose T; Wirthlin L; Zhou P; Wang X; Herrbrich P; Arevalo J; Csik S; Skelton DC; Walker J; Pepper K; Kohn DB; Nolta JA
Mol Ther; 2008 Jul; 16(7):1308-15. PubMed ID: 18461052
[TBL] [Abstract][Full Text] [Related]
14. Preventing and exploiting the oncogenic potential of integrating gene vectors.
Modlich U; Baum C
J Clin Invest; 2009 Apr; 119(4):755-8. PubMed ID: 19348042
[TBL] [Abstract][Full Text] [Related]
15. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
[TBL] [Abstract][Full Text] [Related]
16. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
17. Retrovirus-induced oncogenesis and safety of retroviral vectors.
Nair V
Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.
Zhou S; Fatima S; Ma Z; Wang YD; Lu T; Janke LJ; Du Y; Sorrentino BP
Mol Ther; 2016 Jun; 24(6):1090-1099. PubMed ID: 26957223
[TBL] [Abstract][Full Text] [Related]
20. Insertional gene activation by lentiviral and gammaretroviral vectors.
Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK
J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
